Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Inhibikase Therapeutics director Roberto Bellini received a grant of stock options for 155,000 shares of Common Stock. The options have an exercise price of $1.91 per share and expire on June 26, 2036. Following this grant, he holds 155,000 options directly.
The options will vest on the earlier of June 26, 2027 or the day before the next annual meeting of stockholders, as long as he continues to serve as a director through that date. This is a compensation-related award, not an open-market share purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bellini Roberto
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 155,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 155,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 155,000 options
Exercise price: $1.91 per share
Expiration date: June 26, 2036
+2 more
5 metrics
Options granted
155,000 options
Stock Option (Right to Buy) grant to director
Exercise price
$1.91 per share
Exercise price for the granted stock options
Expiration date
June 26, 2036
Option expiration for the 155,000 granted options
Total options after grant
155,000 options
Total derivative securities held following transaction
Vesting date
June 26, 2027
Latest vesting date, or earlier day before next annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, Grant, award, or other acquisition, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "1.9100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-26T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
annual meeting of stockholders financial
"The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders"
FAQ
What insider transaction did Inhibikase Therapeutics (IKT) report for Roberto Bellini?
Inhibikase Therapeutics reported that director Roberto Bellini received a grant of stock options for 155,000 shares. These options are compensation, not an open-market trade, and give him the right to buy common stock at a fixed exercise price in the future.
How many Inhibikase Therapeutics (IKT) stock options were granted to Roberto Bellini and at what price?
Roberto Bellini was granted 155,000 stock options linked to Inhibikase common shares. Each option has an exercise price of $1.91 per share, meaning he can buy shares at that price once the options vest and before they expire.
When do Roberto Bellini’s Inhibikase (IKT) stock options vest and expire?
The options vest on the earlier of June 26, 2027 or the day before Inhibikase’s next annual stockholder meeting. They expire on June 26, 2036. Vesting requires Bellini to continue serving as a director through the applicable vesting date.
How many Inhibikase (IKT) derivative securities does Roberto Bellini hold after this grant?
After the transaction, Roberto Bellini holds 155,000 stock options directly. Each option is exercisable for one share of Inhibikase common stock at an exercise price of $1.91, subject to vesting conditions and the June 26, 2036 expiration date.